📅 PUBMED DAILY TRIAGE — 2026-05-11

Window: 2026-05-10T09:00Z → 2026-05-11T09:00Z (CRDT) Topics scanned: 10 | Candidates reviewed: ~65 unique articles | Raw PMIDs evaluated: 81 High priority: 3 | Standard: 15 | Low/archive: ~47 (count-only) | Unsolicited finds: 1 Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+, or EARLY_CANCER_DETECTION / NOVEL_TREATMENT flag) — Best Finds by Topic

Cardiovascular-Metabolic

[TR-2026-05-11-001 / PMID 42108331] · The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease (Diabetologia) · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE

First RCT of AID in diabetes + advanced CKD (n=40, 5 sites, Australia+Denmark, randomized crossover): time in range improved 60%→73% (p<0.001), no device-related serious AEs. A historically excluded, high-unmet-need population finally has an RCT-supported answer — AID is safe and effective here.

[TR-2026-05-11-003 / PMID 42108271] · The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial (Nature Medicine) · 6/10 🟠 NOVEL_TREATMENT ⚠️ NEGATIVE PRIMARY ENDPOINT

HF-REVERT: First-in-class miR-132 antisense oligonucleotide tested in 294 post-MI reduced LVEF patients (double-blind, placebo-controlled). Primary endpoint MISSED — LV end-systolic volume index change did not differ between CDR132L groups and placebo. Exploratory subgroup shows potential benefit in advanced baseline remodeling; CDR132L was well-tolerated. HIGH triggered by NOVEL_TREATMENT flag — this is an important Nat Med negative result.

Early Cancer Detection

[TR-2026-05-11-002 / PMID 42108428] · Partnership Driving Impact: An Integrated Women-Centric Model to Improve Early Detection and Treatment of Cervical and Breast Cancer in Ghana and India (Cancer Medicine) · 7/10 🔴 EARLY_CANCER_DETECTION

Real-world LMIC cancer screening program: 25,373 women screened (Ghana + India) for breast and cervical cancer. Ghana: 100% treatment completion for confirmed cases; HPV self-collection accepted by 80% of women. India: 75% HPV self-collection; 52% return for treatment (gap identified). Validates scalable integrated government-NGO-industry model for early detection in high-burden, low-resource settings.

🟢⚪ STANDARD (5–7) — Top by Topic

Cardiovascular-Metabolic

• [TR-2026-05-11-004 / PMID 42108424] · COVID-19 and New-Onset T2D Risk in 42 Million People, England (Diabetes Obes Metab) · 7/10 · Public Health

  Nation-scale linked EHR cohort definitively quantifies COVID-19's T2D contribution as modest + short-term. BMI, deprivation, and ethnicity are far stronger drivers. No T1D association.

• [TR-2026-05-11-010 / PMID 42108418] · Oral Semaglutide Exposure and Outcome-Specific Predictions in T2D (Diabetes Obes Metab) · 6/10 · Drug Development

  Real-world n=256: estimated eCavg adds value for weight and GI tolerability prediction beyond prescribed dose; dose alone suffices for glycaemia. Personalized GLP-1 dosing implications.

• [TR-2026-05-11-011 / PMID 42108208] · Comparative Efficacy of Probiotics for Obesity — Network Meta-analysis, 47 RCTs, n=3555 (Nutr Rev) · 6/10 · Treatment Innovation

  Mix10 (Bifidobacterium+Lacticaseibacillus+Lactobacillus+Streptococcus) tops ranking for weight reduction (MD -2.83 kg vs placebo). Evidence: low-to-moderate certainty; modest effect sizes.

• [TR-2026-05-11-008 / PMID 42108221] · AD-YOLO11: Real-Time Aortic Dissection AI Triage, mAP@0.5=0.951, n=177 (Med Phys) · 6/10 · Diagnostics

  First deep learning model for simultaneous detection of all 3 Type B AD components (TL, FL, FLT) — inference 3ms/slice (GPU). Internal + external validation; promising emergency triage tool.

AI/ML in Clinical Diagnostics

• [TR-2026-05-11-005 / PMID 42108165] · Hyperpolarized ¹²⁹Xe MRI + Interpretable ML for ILD, 93.5% Accuracy, n=155 (Acad Radiol) · 7/10 · Diagnostics

  4-feature decision tree (membrane uptake, VDP, RBC gradient, RBC shift) — COPD 100%/100% sensitivity/specificity, ILD 94.1%/92.9%. Interpretable + bootstrap-validated.

• [TR-2026-05-11-007 / PMID 42108258] · iS2C2: Cointelligent Platform for Disease Cellular Crosstalk Discovery (Signal Transduct Target Ther) · 6/10 · AI/ML + Precision Medicine

  LLM + single-cell RNA-seq + spatial transcriptomics pipeline generating expert-validated AD and cancer hypotheses. Novel paradigm in automated omics-to-hypothesis generation.

• [TR-2026-05-11-009 / PMID 42108286] · Geometry of dMRI Cumulant Series — MS Classification n=1189 (Nat Commun) · 6/10 · Diagnostics

  Rotationally invariant dMRI framework improves MS classification in 1,189 subjects; 1-2 min whole-brain protocols enable clinical translation. Foundation for ML pathology classifiers.

Hematologic Malignancies

• [TR-2026-05-11-013 / PMID 42108389] · Non-Infectious Fever Subgroup in High-Risk MDS — Poorer Survival (Br J Haematol) · 5/10 · Diagnostics

  Multi-institutional Japanese cohort (9 sites): non-infectious fever as novel prognostic clinical feature in high-risk MDS. Abstract-limited; classification confidence medium.

• [TR-2026-05-11-014 / PMID 42108377] · MRD-Guided Early Intervention in MM After ASCT, n=42 (Cancer Med) · 5/10 · Treatment Innovation

  EI at MRD-P onset: TTP 34.8 vs 6.6 months, OS benefit (p=0.034). Very small EI group (n=9). Hypothesis-generating only; authors appropriately note limitations.

• [TR-2026-05-11-015 / PMID 42108355] · Bispecific Antibodies in Hematological Malignancies: Clinical Development Review (Methods Mol Biol) · 5/10 · Treatment Innovation

  Landscape review of approved CD3-redirecting bsAbs (blinatumomab, epcoritamab, mosunetuzumab, etc.) in NHL, MM, AML. J&J Medical Affairs author — note COI. Reference document.

Precision Oncology / Rare Diseases

• [TR-2026-05-11-012 / PMID 42108362] · Intra-pancreatic Fat Deposition: Independent Adverse Prognostic Factor in High-grade panNENs, Multicenter n=87 (Ann Surg Oncol) · 6/10 · Diagnostics

  Pancreas/spleen CT attenuation ratio <0.70 predicts worse OS (HR 2.13) and DSS (HR 2.17) independent of grade/stage. Non-invasive CT biomarker in ultra-rare aggressive tumor.

• [TR-2026-05-11-016 / PMID 42108213] · NLR Predicts Pembrolizumab Outcomes in OPSCC — p16 Interaction, n=64 (Head Neck) · 5/10 · Diagnostics

  Pre-treatment NLR (CBC-derived) inversely predicts PFS and OS on pembrolizumab, significant only in p16+ (HPV+) oropharyngeal cancer. Low-cost biomarker if validated prospectively.

Novel Therapeutics

• [TR-2026-05-11-006 / PMID 42108156] · FRUQUITAS Phase 3 RCT: Fruquintinib + TAS-102 vs TAS-102 in Metastatic Gastroesophageal Cancer (Dig Liver Dis) · 6/10 · Drug Development

  Phase 3 design paper. International intergroup trial (ENGIC-PRODIGE-FFCD). Anti-VEGFR fruquintinib + trifluridine/tipiracil in later-line mOGC. OS as primary endpoint. Results pending.

Aging / Longevity

• [TR-2026-05-11-017 / PMID 42108391] · APOE Genotype × Sex Transcriptomic Landscape in AD — Single-Cell, 54 Cell Types (Alzheimers Dement) · 5/10 · Genomics/Precision Medicine

  Mount Sinai/Mayo single-cell map of sex-by-APOE genotype interactions across 54 brain cell types in AD. Exploratory omics; lays groundwork for sex- and APOE-stratified AD interventions.

💡 UNSOLICITED FINDS

[TR-2026-05-11-018 / PMID 42108202] · Oral Nutrition Interventions in Acute/Critical Care — 16 RCTs, n=3795 (Nutr Rev) · 6/10 · Treatment Innovation

Meta-analysis: oral nutrition interventions associated with hospital mortality improvement (OR 0.50 in 3 trials, 95% CI 0.25-0.98; p=0.04) and 25% reduction at latest follow-up. Evidence quality limited (heterogeneous interventions, mostly acute ward not ICU). High-signal finding outside watchlist — flagged for review.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 7 articles
• Treatment Innovation: 5 articles
• Drug Development: 2 articles
• Public Health: 1 article
• Genomics/Precision Medicine: 2 articles
• Early Detection: 1 article (shared)

By evidence maturity:

• Exploratory: 8
• Validated: 8
• Potentially Practice-Changing: 1 (PMID 42108331)
• ⚠️ Note: One "Validated" is a negative trial (PMID 42108271)

By watchlist topic (reviewed / kept / highest score):

By source type:

• Peer-reviewed journal articles: 18 | Preprints: 0

Topics with zero 8+ articles this run:

• Hematologic malignancies (19th consecutive run with no 8+)
• CBC/ML hematology (19th consecutive empty for true CBC-hematology AI)
• Early cancer detection (no liquid biopsy/ctDNA finds today)
• AI/ML clinical
• Precision oncology/genomics
• Novel therapeutics
• Aging/longevity
• Rare diseases

🔧 RUN NOTES

• No window expansion triggered — 5+ relevant records found within standard 24h CRDT window.
• CBC/ML hematology — 19th consecutive run without a HIGH-priority article. Best find today (PMID 42108165, 129Xe MRI ILD) is an AI/ML imaging study, not hematology-specific CBC/ML work. This topic continues to underperform; consider query refinement for next weekly review.
• Methods Mol Biol 2997 (Bispecific Antibodies) published multiple book chapters indexed this window. All scored 3-5/10 as methodology/review chapters. 7 of 10 immunotherapy topic candidates were from this single book volume. Query improvement: add NOT ("Book Chapters"[pt]) OR filter for Journal Article pub type in future runs.
• CDR132L (PMID 42108271): HIGH by NOVEL_TREATMENT flag. ⚠️ PRIMARY ENDPOINT MISSED. Alert message clearly marked as negative trial result. Downstream pipeline should log as negative evidence for miR-132 pathway in post-MI cardiac remodeling.
• Rolling 7-day view: Cardiovascular-metabolic has been the strongest topic for 3 consecutive runs. Early cancer detection produced two 9/10 articles on 2026-05-09 but was quiet today. CBC/ML hematology remains a consistent underperformer across the past 19 runs.
• humans[MeSH] filter applied to aging/longevity searches — reduced non-human noise as planned per v1.2 protocol.
• 81 unique PMIDs retrieved across all topics; 65 assessed at abstract level; 16 older-CRDT articles (42107614-42106920) assessed as count-only LOW after initial topic review.